Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1 (BRIGHTE study) )

Trial Profile

A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1 (BRIGHTE study) )

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fostemsavir (Primary)
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms BRIGHTE
  • Sponsors Bristol-Myers Squibb; GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK; ViiV Healthcare
  • Most Recent Events

    • 12 Dec 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
    • 18 Oct 2023 According to a ViiV Healthcare media release, data from this study will be presented at the 19th Annual European AIDS Conference (EACS 2023)
    • 26 Sep 2023 Results of 240-week efficacy and safety of fostemsavir + OBT in adults with multidrug-resistant human immunodeficiency virus , published in the Infectious Diseases and Therapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top